Abstract: It has been well established that patients with schizophrenia have impaired cognitive abilities on neuropsychological tasks related to memory. Previous studies also suggest a central role for serotonin in memory. This double-blind crossover study aimed to explore the effect of L-tryptophan, a serotonin precursor, on a variety of memory tasks in schizophrenic patients. Antipsychotic-treated schizophrenic patients in remission (N ϭ 21) were randomly treated with L-tryptophan or placebo and then evaluated at three consecutive points on clinical measures (including Positive and Negative Syndrome Scale for Schizophrenia, Clinical Global Impression, and Extrapyramidal Symptoms Rating Scale) and by neuropsychological tests (including Digit-Span, Paired Association, Rey-Osterich Complex Figure Test , Digit Symbol, Number Facility Test, and the Rivermead Behavioral Memory Tests. Compared with placebo, L-tryptophan had a beneficial effect on memory functions but not on the patients' psychotic state or on the side effects of medications. These preliminary results suggest the possibility of using serotonin precursor to enhance memory function in schizophrenia. (J Nerv Ment Dis 2003;191: 568 -573) 
C ognitive dysfunction is a distinctive characteristic of schizophrenia. Patients with schizophrenia display impaired cognitive abilities on neuropsychological tasks related to attention, memory, and executive function (Rund and Borg, 1999) . Since the 1960s, experimental findings have demonstrated deficits in verbal and visual short-term memory among people with schizophrenia (Aleman et al., 1999; Calev et al., 1987; Levin et al., 1989; Sharma and Mockler, 1998) . Impaired long-term memory (Saykin et al., 1991) and procedural memory (Schmand et al., 1992) have also been noted in schizophrenia. Studies of pharmacological agents that potentially limit memory impairment in schizophrenia are particularly important in the rehabilitation of these patients.
Various animal studies have shown that the stimulation or blockade of different presynaptic and postsynaptic serotoninergic receptors and uptake/transporter sites can prevent memory impairment and facilitate learning (Buhot et al., 2000; Levkovitz and Segal, 1994; Levkovitz and Segal, 1996; Malleret et al., 1999) . Human studies have provided growing evidence that the serotoninergic (5-HT) system plays a significant role in learning and memory (Buhot, 1997; Buhot et al., 2000) . In fact, regional distribution of 5-HT pathways, the 5-HT reuptake site/transporter complex, and 5-HT receptors has been demonstrated in the brain in the areas associated with memory function. Many human studies agree that the 5-HT system may be important in normal memory function, pathogenesis, or both, and in the treatment of cognitive disorders (Gold and Harvey, 1993; Green et al., 1997; Hagger et al., 1993; Keefe et al., 1999; Tamlyn et al., 1992) , and that alterations in serotonin levels may improve memory impairment in schizophrenia. These earlier speculations have been verified by recent evidence showing that cognitive performance can be enhanced by giving a 5-HT(1A) agonist to patients suffering from schizophrenia (Sumiyoshi et al., 2001a; 2001b) .
Several studies on healthy volunteers have found that acute L-tryptophan depletion specifically impaired long-term memory formation (Luciana et al., 1998; McEntee and Crook, 1991; Riekkinen et al., 1991; Steckler and Sahgal, 1995) . In this double-blind crossover study, we examined the effects of L-tryprophan, the natural amino acid precursor of 5-HT, on a variety of memory tasks among people with schizophrenia.
at least 6 months participated in the study. Diagnosis was confirmed by at least two senior psychiatrists using the Structured Clinical Interview. The subjects were outpatients who had been on fixed doses of haloperidol (5 to 10 mg/d) or perphenazine (16 to 24 mg/d) with or without trihexyphenidyl (5 to 10 mg/d) or biperiden (2 to 4 mg/d) for a minimum of 6 months. The study was approved by the National Institutional Review Board. All study participants gave signed informed consent. Their demographic characteristics are summarized in Table 1 .
Assessments

Psychiatric Evaluation
The subjects were clinically evaluated before receiving either L-tryptophan or placebo (baseline) and during each of the stages of the study by the following instruments: Positive and Negative Syndrome Scale for Schizophrenia (PANSS) for evaluation of illness severity, Clinical Global Impression (CGI) for general clinical assessment, and Extrapyramidal Symptoms Rating Scale (ESRS) for the evaluation of possible psychomotoric adverse effects.
Psychological and Cognitive Tests
A short version of the WAIS-R, which has been found to correlate highly with IQ (Gold and Harvey, 1993) , was administered to screen out people with an IQ below 70, who were excluded from the study. This included subtests for information, block design, and similarities.
Number Facility Test
This instrument tests vertical addition of three two-digit numbers. The number of successful additions completed within 90 seconds was scored. Because memory function is not tested here, subjects were provided with pencil and paper.
Memory Tests
We used a heterogeneous group of memory tests in the present study, including both traditional memory tests and the newer behavioral memory tests. The traditional tests are widely used and well known, e.g., the digit span. The behavioral memory tests are a newer group of tests that aim at evaluating memory through behavioral functions closer to the demands of daily living, e.g., the Rivermead Behavioral Memory Tests (RBMTs). This latter test has been used to evaluate cognitive functions in different patient populations, including patients suffering from methylene dioxyamphetamine (MDMA) neurotoxicity (Parrott, 2000) , normal aging (Ostrosky-Solis et al., 1998), and Parkinson disease (Dalrymple-Alford et al., 1995) . The specific memory tests used in the current work are the following:
Digit Span (WAIS-R Subtest)
The subjects were asked to repeat a list of two-digit numbers. With each successful repetition, another number was added to the list. The score was based on the number of two-digit numbers successfully recalled (Verdoux et al., 1995) .
Paired Association
The subjects were given 10 pairs of words on separate cards to read aloud. The first word of each pair was then presented, and the subject was asked to recall the paired word. Incorrect or omitted responses were corrected. After five trials, the number of paired words correctly recalled was scored (Lezak, 1976) .
Rey-Osterreith Complex Figure Test
An 18-item complex figure was presented, and subjects were asked to copy the figure and then draw it from memory, focusing on shape and location. The maximal score was 36 (Osterrieth, 1944) .
Digit Symbol (WAIS-R Subtest)
Nine digits and their associated symbols were presented, and the subjects substituted a list of digits with the appropriate symbols. The score was based on the number of symbols correctly substituted within 90 seconds (Wechsler, 1981) .
Rivermead Behavioral Memory Tests
This test examines memory functions related to daily activities (Wilson et al., 1989) . Subtest 1, Remember a Name. A photograph of a face was presented while the first and last names were read out. The subject was then asked to recall the full name of the person in the photograph. Subtest 2, Remember a Hidden Belonging. The subjects were asked to retrieve a personal item hidden in their presence. Successful retrieval of the item earned a maximal score of 4 points. Subtest 3, Remember an Appointment. In advance, the subject was instructed to ask, "When is the next meeting?" when an alarm clock rang after 20 minutes. The maximal score was 2 points. Subtest 10, Pass a Message. At the last station, the subject was required to take the envelope and to replace it at the correct station. The maximal score was 3 points. Subtest 11, Orientation. Ten general orientation questions were asked (e.g., "What year is it? Who is the Prime Minister?"). The maximal score was 10 points. Two scores were produced for each of these subtests, i.e., a simple pass/fail or screening score and a standardized profile score that ranged between 2 (normal), 1 (borderline), and 0 (abnormal), enabling cross-subtest comparisons. The RBMT screening score ranged from 0 to 11, and the profile score ranged from 0 to 22 (Wilson et al. 1989) . The profile of the tests is summarized in Table 2 .
L-Tryptophan Treatment
L-Tryptophan (Optimax; Merck, London, United Kingdom) was prepared in 333-mg capsules, as were identical placebo capsules. The drug was administered as a supplement to the antipsychotic treatment. The daily dose was 1 g/d (in three divided doses because of L-tryptophan's 6-hour halflife), and this dosing schedule continued for 4 days. This dose was selected based on reports of the use of L-tryptophan for the treatment of sleep and depressive disorders (Herrington et al., 1976) . There is much heterogeneity in dosing schedules of L-tryptophan (Meyers, 2000) . We used a relatively short period because it was shown to be effective in raising the levels of both serum tryptophan (Bjork et al., 2000; Cleare and Bond, 1995) and the CSF 5-HT metabolite (Young and Gauthier, 1981) , and because an earlier evaluation was expected to avoid a possible antidepressant effect. Eosinophilic myalgia syndrome, a result of contaminated L-tryptophan produced by a fermentation process (Lader, 1994) , was not associated with Optimax.
Experimental Design
We chose the crossover study design suggested by others as providing an efficient way to compare added treatments in chronic disease (e.g., schizophrenia) requiring chronic medication (e.g., antipsychotics) (Cleophas and Travenier, 1995; Jones and Donev, 1996) . This design reduces the within-subject variability and facilitates recruitment of patients. During the first phase of the study, the patients were clinically evaluated and tested on all memory tests and familiarized with the experimental set-up. Each patient was then randomly assigned to either the L-tryptophan group or the placebo group. The patients were supplied with the appropriate capsules (1 mg/d for 4 days) and were instructed in their use. After 4 days, the patients were again clinically evaluated and tested on all memory tasks. In the third stage, patients were crossed over so that the L-tryptophan-treated patients received the placebo capsules and vice versa. After 4 days, the patients were clinically evaluated and tested on all memory tasks.
Statistical Analyses
We applied analyses of variance (ANOVAs; repeated measures, within-group design) to test whether there were significant differences among baseline, placebo, and L-tryprophan treatment on clinical and neuropsychological 
RESULTS
Effect of L-Tryptophan
No significant effect was found for the order of the administration of L-tryptophan and placebo. The effect of L-tryptophan was compared with placebo by means of averaging across-group with repeated ANOVA measurements, permitting within-subject comparison of the treatment effect. Administration of L-tryptophan produced no significant changes in the psychiatric parameters as evaluated by the PANSS (total PANSS, F ϭ 3.17, df ϭ 2, p ϭ .66; positive symptoms, F ϭ .13, df ϭ 2, p ϭ .87; negative symptoms, F ϭ .28, df ϭ 2, p ϭ .97; general symptoms, F ϭ 1.6, df ϭ 2, p ϭ .22), CGI (F ϭ 1.0, df ϭ 2, p ϭ .33), or ESRS (F ϭ 1.0, df ϭ 2, p ϭ .98). Treatment with L-tryptophan did, however, significantly improve performance on the following: Digit Symbol, Paired Association, Rey-Osterich Complex Figure Test , and RBMTs. Performance was not affected on the Digit Span and the Number Facility Tests (Table 3) .
Because the RBMT was found to be sensitive in detecting impairments in everyday behavioral memory, the performance on each of the subtests was analyzed. L-Tryptophan was found to improve patient performance on all the RMBT subtests (Table 4) .
DISCUSSION
Short-term L-tryptophan significantly improved memory on tests for visuospatial memory, working memory, psychomotor speed, and visual-motor coordination when compared with placebo.
The subjects in this study were patients with schizophrenia who were being treated chronically with typical antipsychotic medications. This group of patients was selected for several reasons. First, schizophrenic patients in remission have only minimal positive symptoms to interfere with memory function. Second, our aim was to improve memory function in well treated schizophrenic patients. Finally, the minimal serotoninergic activity of the typical antipsychotics does not interfere with the study of serotonergic effect on memory in schizophrenic patients in remission. It is important to note that some of our patients received anticholinergic medications that may have had an effect on memory functions (Aleman et al., 1999) . The crossover design of the study was intended to overcome this drawback.
We found that short-term administration of L-tryptophan significantly improved traditional and behavioral memory function. The improvement in memory associated with L-tryptophan can be attributed to several factors: L-tryptophan's effect on serotonergic activity, enhancing cognitive function (Steckler and Sahgal, 1995) , and L-tryptophan's indirect effect on the cholinergic or the dopaminergic systems, also associated with cognitive enhancement (Friedman et al., 1999; Little et al., 1995; Murphy et al., 1996) . The presented results support the notion that the effect is related to memory, and not to other cognitive functions. There was no effect on orientation or on the number facility test. Further possibilities include L-tryptophan's beneficial effect on memory by reducing adverse effects of antipsychotic medication therapy or by L-tryptophan's reported alleviation of mood and sleep disorders (Korner et al., 1986) . The fact that extrapyramidal syndrome scores were not changed with the administration of L-tryptophan in our study argues against the first possibility. The short period (only 4 days before evaluation) would argue against the second possibility, because mood changes usually take at least 2 weeks to evolve (Meyers, 2000) . It is also worth noting that, as a general rule, and as has been shown in other studies (Perez and Godoy, 1998) , the findings of traditional and behavioral memory tests were in accord.
Limitations of the present study include its relatively small sample size and the lack of L-tryptophan levels to enable correlation of memory enhancement. Additionally, one may argue against the relatively short tryptophan loading and the lack of formal evaluations of sleep and mood. We contend that more research on these issues is needed, both on a clinical level (i.e., can serotonergic enhancement help memory in patients suffering from schizophrenia?) and on a more theoretical level (i.e., what is the role of the serotonergic system in memory and schizophrenia?).
To conclude, our preliminary results suggest that L-tryptophan may improve memory in patients with schizophrenia.
